NOVO B Stock Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.871.30 |
| 52 Week High | kr.932.00 |
| 52 Week Low | kr.504.40 |
| Beta | 0.20 |
| 1 Month Change | -4.69% |
| 3 Month Change | 18.98% |
| 1 Year Change | 55.28% |
| 3 Year Change | 280.44% |
| 5 Year Change | 438.67% |
| Change since IPO | 32,230.25% |
Recent News & Updates
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14
Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?
Mar 18Recent updates
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?
Mar 18Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings
Dec 30Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly
Dec 12Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)
Nov 24Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)
Aug 20These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely
Aug 02Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)
May 22These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely
May 04Novo Nordisk (CPH:NOVO B) Will Pay A Larger Dividend Than Last Year At DKK8.15
Feb 04Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet
Feb 02Shareholder Returns
| NOVO B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 0.6% | -0.4% | -0.3% |
| 1Y | 55.3% | 4.8% | 23.7% |
Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: NOVO B exceeded the Danish Market which returned 23.7% over the past year.
Price Volatility
| NOVO B volatility | |
|---|---|
| NOVO B Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.1% |
| 10% least volatile stocks in DK Market | 2.9% |
Stable Share Price: NOVO B has not had significant price volatility in the past 3 months.
Volatility Over Time: NOVO B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 63,845 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOVO B fundamental statistics | |
|---|---|
| Market cap | kr.3.89t |
| Earnings (TTM) | kr.83.68b |
| Revenue (TTM) | kr.232.26b |
46.5x
P/E Ratio16.7x
P/S RatioIs NOVO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVO B income statement (TTM) | |
|---|---|
| Revenue | kr.232.26b |
| Cost of Revenue | kr.35.77b |
| Gross Profit | kr.196.50b |
| Other Expenses | kr.112.81b |
| Earnings | kr.83.68b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 18.76 |
| Gross Margin | 84.60% |
| Net Profit Margin | 36.03% |
| Debt/Equity Ratio | 20.0% |
How did NOVO B perform over the long term?
See historical performance and comparison